Full-Time

Director – Biostatistics

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Compensation Overview

$245k - $260kAnnually

+ Bonus + Equity Grant

Expert

San Carlos, CA, USA

Relocation assistance offered if required.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • MS/MA degree in related discipline and 12 years of relevant experience, or PhD in related discipline with 8 years of relevant experience in Pharmaceutical/Biotechnology industry. Some experience in oncology is desired.
  • Strong knowledge of CDISC and SAS programming.
  • Understanding of appropriate regulations, industry standards and guidance documents.
  • Excellent communicator, collaborator, and creative thinker.
Responsibilities
  • Provide leadership and guidance as the statistical expert on clinical program teams.
  • Lead statistical discussions with external parties including Health Authorities and joint development partners.
  • Provide statistical strategic input into clinical documents e.g., Regulatory Briefing Document, Investigator Brochure, etc.
  • Collaborate with project team members and CROs to generate clinical protocol, author statistical analysis plan/TLF templates, analyze specifications, CRFs, and CRF edit checks.
  • Perform analysis, interpret study results, and collaborate with clinical team to conduct interim data review, final reports, and publications.
  • Support ongoing publication tasks.
  • Oversee the activities of FSP and CRO biostatistics teams, ensuring high quality deliverables within study budget and timeline.
  • Manage and mentor junior statisticians.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the body's immune response to fight illnesses. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The main goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

5%

1 year growth

22%

2 year growth

61%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnership with Kite accelerates development and commercialization of therapies.
  • FDA support expedites approval process for Arcellx's innovative treatments.
  • Advancements in gene editing enhance precision of Arcellx's cell therapies.

What critics are saying

  • Competition from established CAR-T therapies like Abecma and Carvykti.
  • Dependency on Kite partnership could pose risks if dynamics change.
  • Phase 3 trial for anito-cel carries risk of not meeting endpoints.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track, Orphan Drug, and RMAT designations.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced antigen binding.

Help us improve and share your feedback! Did you find this helpful?